ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

OPC 131461

A development code. Also written as “OPC-131461”, “OPC 131461 10mg group” and “OPC 131461 5mg group”.

Its studies are mostly in Heart Failure, led by Otsuka.

Furthest: phase 2, since Nov 7, 20222 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka20 open or runningphase 2since Nov 7, 2022Nov 7, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2022First study: phase 2 study in Edema, CardiacFirst studyNCT05615363 · 157 enrolled · Japan
  2. Jan 22, 2025Phase 2 study in Heart FailureNCT06795399

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06795399Heart Failure2WithdrawnMay 25, 20250
NCT05615363Edema, Cardiac · Japan2CompletedOct 21, 2024157

How it is read

Names in the registry

  • “OPC-131461”, 1 entry
  • “OPC 131461 10mg group”, 1 entry
  • “OPC 131461 5mg group”, 1 entry
  • “OPC 131461 2mg group”, 1 entry
  • “OPC 131461 1mg group”, 1 entry

Codes read as this program: OPC131461.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.